rSM PROGRESS. DESTINATION PATIENTS.
Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients.

Arrakis in the News

April 18, 2019
STAT – The Readout Loud biotech podcast
Drugging the undruggable
Biotech entrepreneur Michael Gilman dials in to talk about his company’s efforts to craft pills that can do what has thus far proved impossible.
November 28, 2017
Nature Reviews Drug Discovery
Small molecules against RNA targets attract big backers
November 6, 2017
C&EN (Chemical & Engineering News)
Arrakis is selected as one of C&EN’s Ten Start-Ups to Watch: “Meet the master builders behind chemistry’s most intriguing young companies.”
Ten Start-Ups to Watch
August 8, 2017
Xconomy
Arrakis is selected as a finalist for the Xconomy Awards as Big Idea of the year. Winners will be announced on September 26.
Xconomy Award Finalists
March 2, 2017
BioCentury Innovations
RNA, Meet Small Molecules
February 28, 2017
BioWorld Today
Gilman-led Arrakis Lands $38M Series A Round
Back to Top